The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance

Journal of Clinical Investigation

Volumn 107, Issue 4, 2001, Pages 449-455

  Ono, Suzane Kioko ^a,b   Kato, Naoya ^a   Shiratori, Yasushi ^a   Kato, Jun ^a   Goto, Tadashi ^a   Schinazi, Raymond F ^c   Carrilho, Flair José ^b   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CARBOVIR; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; DRUG MECHANISM; DRUG SENSITIVITY; HEPATITIS B VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0035114188     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI11100     Document Type: Article

References (54)

1. Hepatitis drugs win approval
2. Histological improvement in patients with chronic hepatitis B virus infection treated with lamivudine
3. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group
4. Treatment of chronic hepatitis B infection
5. Antiviral therapy for hepatitis B and C in Asians
6. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
7. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine
8. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo
9. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group
10. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy
11. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy
12. Long-term incidence of hepatitis B virus resistante to lamivudine in human immunodeficiency virus-infected patients
13. Significance of mutations in the hepatitis B virus polymerase selected by nucleoside analogues and implications for controlling chronic disease
14. Long-term lamivudine therapy for chronic hepatitis B
15. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements
16. Primary structural comparison of RNA-dependent polymerases from plant, animal and bacterial viruses
17. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection
18. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective
19. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA
20. Evolution o f hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
21. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
22. Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis
23. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
24. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors
25. BMS-200475, a novel carbocyclic 2′-denxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro
26. Growth of human hepatoma cells lines with differentiated functions in chemically defined medium
27. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA
28. A transforming growth factor beta type II receptor gene mutation common in sporadic cecum cancer with microsatellite instability
29. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients
30. Changes of hepatitis B virus DNA in liver and serum caused by recombinant leukocyte interferon treatment: Analysis of intrahepatic replicative hepatitis B virus DNA
31. Lamivudine as initial treatment for chronic hepatitis B in the United States
32. Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance
33. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
34. Anti-hepatitis B virus activity and metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L(-)-5- fluorocytidine
35. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyl uracil
36. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay
37. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
38. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel
39. Resisting resistance: Maximizing the durability of antiretroviral therapy
40. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy
41. Biphasic clearance kinetics of hepatitis B virus from patients during adefovir dipivoxil therapy
42. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
43. Adefovir dipivoxil treatment of hepatitis B virus disease in patients failing lamivudine therapy
44. Antiviral agents in hepatitis B virus transfected cell lines: Inhibitory and cytotoxic effect related to time of treatment
45. Inhibitory effect of 9-(2-phosphonyl-methoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
46. Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine (D4FC) analogues: Discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase
47. Inhibitory effect of 2′-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication
48. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
49. 2′,3′-dideoxy-2′,3′-didehydro-b-l-5-fluorocytidine (b-l-fd4c) exhibitsa more potent antiviral effect than lamivudine in chronically WHV infected woodchucks
50. In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks
51. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks
52. Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy
53. Combined therapeutic modalities for viral infections: Rationale and clinical potential